Phase 2b Clinical Trial of Arbaclofen in Autism Has Disappointing Results

Phase 2b Clinical Trial of Arbaclofen in Autism

Seaside Therapeutics reports the study did not show improvement on the primary endpoint of social withdrawal, but it did demonstrate improvement on the Clinical Global Impression of Severity scale.

Chemical structure of arbaclofen.Read the article:

http://www.marketwatch.com/story/seaside-therapeutics-to-announce-results-from-a-phase-2b-clinical-trial-of-arbaclofen-in-autism-spectrum-disorder-at-the-international-meeting-for-autism-research-imfar-2013-conference-2013-05-01

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.